Manufacturers of regenerative medicine products will get a welcome boost from US FDA under the 21st Century Cures Act, says Michael Werner, executive director of trade group the Alliance for Regenerative Medicine
Several clauses within the legislation, which was approved by the House on Nov. 30 and is expected to pass the Senate this week, address the future of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?